Preventing Both EBV Infection and EBV-Associated Diseases: Advances in Vaccine Research

Area of Science:

• Virology
• Oncology
• Vaccinology

Background:

• Epstein-Barr Virus (EBV) is a human oncovirus linked to numerous cancers, with over 90% global adult infection rates.
• EBV-attributable cancers represent a significant global health burden, highlighting the need for preventative measures.
• Currently, no licensed EBV vaccine is available for widespread clinical use.

Purpose of the Study:

• To review the current status and recent advancements in Epstein-Barr Virus (EBV) vaccine research.
• To summarize progress across various vaccine platforms for EBV.
• To provide a foundation for future EBV vaccine development and clinical application.

Main Methods:

• Systematic review of recent scientific literature on EBV vaccine research.
• Analysis of progress in different vaccine platforms.
• Assessment of clinical trial data for promising EBV vaccine candidates.

Main Results:

• Several promising EBV vaccine candidates have emerged, with some progressing to clinical trials.
• Advances in vaccine technology, spurred by COVID-19 vaccine development, are accelerating EBV vaccine research.
• Progress has been made across diverse vaccine platforms, including mRNA, viral vectors, and subunit vaccines.

Conclusions:

• The development of effective EBV vaccines is gaining momentum, offering hope for preventing EBV infection and EBV-associated malignancies.
• Continued research and clinical evaluation of EBV vaccine candidates are crucial for their future translational application.
• EBV vaccines hold substantial potential for reducing the global burden of EBV-related cancers.